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Abstract
Background: The epidemic of HIV/AIDS and treatments that have emerged to alleviate, have
brought about a shift in the burden of disease from death to quality of life/disability. The aim was
to determine which factors are associated with improvements in the level of health of male and
female patients with HIV/AIDS in Andalusia, in terms of disability-adjusted life years.
Methods: Descriptive study based on a sample group of 8800 people on the Andalusian AIDS
register between 1983 and 2004. Dependent variables: Life lost due to premature mortality (YLL),
years lost due to disability (YLD) and disability-adjusted life years (DALY). Independent variables:
vital state, sex, age at the time of diagnosis, age at the time of death, transmission category, province
of residence, AIDS-indicator disease and the period of diagnosis. A bivariate analysis was carried
out to find out if the health level variables changed in accordance with the independent variables.
Using the independent variables which had a statistically significant link with the level of health
variables, a multivariate linear regression model, disaggregated by gender, was constructed.
Results: Amongst the women, we found a model which explained the level of health of 64.9%: a
link was found between a higher level of health (lower DALYs) and not intravenous drug use, the
province of residence, being diagnosed during the HAART era and older age at the time of
diagnosis. Amongst the men, we found a model which explained the level of health of 64.4%: a link
was found between a higher level of health (lower DALYs) and intravenous drug use, the province
of residence, being diagnosed during the HAART era and older age at the time of diagnosis.
Conclusion: A higher level of health (lower DALY) amongst both men and women was found to
be linked to not be intravenous drug user, the province of residence, being diagnosed during the
HAART era and older age at the time of diagnosis.
Background
The human immunodeficiency virus (HIV) and acquired
autoimmune deficiency syndrome (AIDS) epidemic con-
stitutes a large-scale worldwide public health problem,
with important demographic, social and economic reper-
cussions. HIV/AIDS has resulted in the deaths of more
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1981. This means that it is one of the most destructive epi-
demics in living history [1].
HIV/AIDS has been classified as a chronic disease [2]. The
WHO uses this term for diseases which last a long dura-
tion, there are many opportunities for prevention and
they require a long-term and systematic approach to treat-
ment. It is therefore very important to find out about the
different ways in which HIV affects mortality rates within
the infected population and to identify the factors associ-
ated with better levels of health. By reading the literature,
we can see that the most important factors studied which
can be linked to lower health scores are sex, level of edu-
cation or socioeconomic level, the virus transmission cat-
egory, age and geographical location.
In terms of AIDS incidence and mortality rates, previous
studies have shown that there are differences between
men and women, although these differences are not
always the same in all cases. In Spain, incidence and mor-
tality rates are different, in accordance with these trends
[3].
The most common transmission method in Spain has
been through the use of intravenous drugs. Many different
studies have shown the differences in the advance of the
disease amongst intravenous drug users in comparison
with patients who contracted the disease in other ways.
Patients who use drugs tend to have a poorer prognosis.
Although these differences also vary between regions
[4,5].
With regard to differences between regions, there is great
variation in less developed countries such as Brazil. Brito
[6] examined the characteristics of the AIDS epidemic
between regions and found that, from 1996 onwards, the
incidence rate of AIDS amongst adults in Brazil and Sao
Paulo was reaching a stable plateau, while in northwest
Brazil incidence rates of the illness continued to increase.
In addition, Szwarcwald [7] found that AIDS incidence
rates were higher around the port of Rio de Janeiro. She
also found that the number of cases amongst women
increased during the final phase of the study (post-
HAART), with higher incidence rates in the poorest areas.
In Europe, analyses of large areas have revealed that there
is not much variation. Van Astern [8] studied HIV/AIDS
mortality rates in European countries and the results
showed that there was little geographical variation. How-
ever, analyses of smaller areas have revealed some varia-
tion. For example, Giovannetti [9] found differences in
AIDS mortality rates between residents of coastal areas
and other provinces in Italy both before and after the
introduction of HAART, and concluded that the variations
may reflect differences in the composition of the groups
and access to treatment. Spain has a comprehensive
health system of universal coverage, and offers HAART as
one possible treatment. It is therefore unlikely that there
would be any significant intra-territorial variations.
In terms of levels of education and socioeconomic levels,
studies have shown that, in a number of different settings,
patients with a higher level of education have a better
prognosis [6,10-12] and a higher medication adherence
rate [6].
Specialist studies have shown that physical quality of life
decreases as HIV progresses, as a result of symptoms and
antiretroviral treatment [13]. As such, scores to measure
patients' level of health, such as Disability-Adjusted Life
Years (DALY), are more appropriate than mortality or sur-
vival rates when it comes to studying the impact of this ill-
ness or the associated "burden of disease", as they provide
more information, taking into account not only that
patients live for longer, but that their quality of life is also
better. A patient's DALY represents the current value of the
number of years of life free from disability that he or she
will live, which are lost or gained as a result of premature
death or disability during a certain year [14].
The aim of this study is to determine which factors are
associated with improvements to the level of health of
male and female patients with HIV/AIDS in Andalusia, in
terms of disability-adjusted life years.
Methods
Design
Descriptive study. 9699 people included on the Andalusia
AIDS Register between 1983 and 2004 were considered
for the study. 246 were excluded because there was no
date of death, 482 because there was no date of diagnosis
and a further 171 because their place of residence was out-
side Andalusia. The final population taken into account
for this study was 8800 people.
The data used for this study were extracted from the Anda-
lusian Register of AIDS cases, which forms part of the
national system of epidemiological monitoring in which





Disability-adjusted life years can be calculated using the
following equation:
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Life lost due to premature mortality (YLL)
The YLL is an estimated figure reflecting the number of
years lost as a result of premature death based on a prede-
termined life expectancy. The YLL is calculated based on
the life expectancy at the age of death obtained via a stand-
ard life table with a low mortality [15].
Years lost due to disability (YLD)
The YLD is an estimate of the number of years that a
patient has lived with a disability [15]. YLD = N* D
Ni = Duration of (years lived) with the illness for the
patient i.
D = Value reflecting disability between 0 = maximum
health and 1 = death.
For the purposes of this study, we have used the results of
research carried out by [16] with the European Disability
Weights Group, which assigns Spain a value of 0.65 for
HIV/AIDS for this indicator.
Independent Variables
Vital State
This is the information collected regarding the vital state
of HIV/AIDS patients on the 31st of May 2005. There are
two possible categories: alive or dead.
Sex
Two possible categories: male or female.
Age at the Time of Diagnosis
A continuous variable calculated based on the patient's
date of diagnosis and date of birth.
Age at Time of Death
A continuous variable calculated based on the patient's
date of death and date of birth.
Transmission Category
This variable reflects the reason why the illness was trans-
mitted, taking into account whether or not the individual
belongs to a risk group of some sort. This variable has four
categories: homosexual, heterosexual, intravenous drug
user and other.
• The "homosexuals" category refers to homosexual indi-
viduals who engage in sexual relations entailing risk, i.e.
without using a condom.
• The "heterosexuals" category refers to heterosexual indi-
viduals who engage in sexual relations entailing risk, i.e.
without using a condom.
• The "other" category includes categories with few cases,
such as recipients of blood products, children of at-risk
mothers, patients infected by blood transfusions, and
unknown cause.
Province of Residence
Province of residence of the patient at the time of diagno-
sis.
Diagnosis Period
Three diagnosis periods have been used based on the level
of implementation of HAART in Spain: pre-HAART
(before 1996), limited use of HAART (1997 and 1998)
and HAART (after 1998).
Analysis
A bivariate analysis was carried out to find out if the
health level variables changed in accordance with the
independent variables (DALY, YLL and YLD). The inclu-
sion of these variables is justified according to previous
studies detailed in the literature. The Student's t-test and
ANOVA table were used to examine the qualitative varia-
bles with variance homogeneity and normal distribution,
and the other variables were analysed using the Mann-
Whitney U-test and the Kruskall Wallis H-test. The contin-
uous independent variables were examined using linear
regression analysis. All of the analyses were carried out
independently for the men and women in the sample
group.
Using the independent variables which proved to have a
statistically significant link with the DALY variable, we
constructed two multivariate linear regression models –
one for the men and one for the women.
Healthleveli = β0 + β1Ri + β2Di + β3Ii + β4Ai
where Health leveli is the dependent variable of the (DALY)
level for a person with HIV/AIDS i
Ri: Route of infection
Di: Place of residence
Ii: Period of diagnosis
Ai Age at the time of diagnosis
Todos los análisis fueron efectuados con el software SPSS
for Windows 14.0.
The research commission of the institution granted ethical
approval for the study.Page 3 of 9
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Table 1 provides basic data about patients infected with
HIV/AIDS in Andalusia. Of all the subjects included in the
study, 7375 were men (83.8%). 60.9% of the subjects
died during the study period, 51.4% of the women and
62.7% of the men. The most frequent route of HIV infec-
tion was through intravenous drug use (56.28 for Women
and 74.01 for men).
With regard to the province of origin of patients with HIV/
AIDS, the province with the least cases in Andalusia was
Jaen (444), followed by Huelva and Almeria, with 511
and 600 cases respectively. The provinces with the most
cases were Cadiz (1541), Seville (1713) and Malaga
(1511).
The average age for AIDS diagnosis was 33.7 years of age.
The average age at the time of diagnosis was 31.3 years for
women (SD 10.5) and 34.1 for men (SD 9.0). The average
survival time for those infected with HIV/AIDS was 49.6
months (SD 50.4) and the average age at time of death
was 36.3 for women (SD 10.5) and 38.6 for men (SD 9.3)
(Table 2).
In terms of the level of health, the average DALY for
patients with HIV/AIDS in Andalusia was 33.01 (SD
21.98) – 31.15 for the women (SD 24.78) and 33.37 for
the men (SD 21.38). The average number of Years of Life
Lost due to HIV/AIDS was 29.06 (SD 24.36) – 26.82 for
the women (SD 27.09) and 29.49 for the men (23.77).
The average value of Years Lived with Disability due to
HIV/AIDS was 3.95 (SD 4.06) – 4.33 for the women (SD
4.16) and 3.88 for the men (4.04).
Variables Associated with Improved Levels of Health
Model for the Women
In the bivariate analysis, female intravenous drug users
had lower levels of health, i.e. they had higher YLLs, YLDs
and DALYs due to HIV/AIDS (YLL = 29.4, YLD = 4.58 and
DALY = 34.03) than those who did not use intravenous
drugs (YLL = 23.4, YLD = 3.99 and DALY = 27.43) (Table
3).
In terms of levels of health and the place of residence at
the time of diagnosis, a link was found between being a
resident of Cordoba and higher Years of Life Lost (p =
0.036) and higher DALYs (p = 0.039). Likewise, a link was
found between living in Malaga and having a lower YLD.
In addition, a link was found between living in Granada
at the time of diagnosis and lower YLLs (p < 0.001),
higher YLDs (p = 0.020) and lower DALYs (p < 0.001).
A link was found between older age at the time of diagno-
sis and lower Years of Life Lost due to the illness (Coeffi-
cient = -0.446), lower Years of Life with Disability
(Coefficient = -0.087) and lower Disability-Adjusted Life
Years (Coefficient = -0.533).
In the multivariate analysis with linear regression a model
was found which explained 24.5% (Coefficient of deter-
mination = 0.245) of the level of health (DALY) (Table 4).
A higher level of health (lower DALY) was found to be
Table 1: Descriptive Analysis of the Population Studied. 
VARIABLE Total Women Men
n % n % n %
Deceased
No 3440 39.1 693 48.63 2747 37.25
Yes 5360 60.9 732 51.37 4628 62.75
Route of Infection
IVDU 6260 71.1 802 56.28 5458 74.01
Heterosexual 1174 13.3 468 32.84 706 9.57
Homosexual 763 8.7 0 0.00 763 10.35
Other 492 5.6 149 10.46 343 4.65
Province of residence at diagnosis
Jaen 444 5.0 81 5.68 363 4.92
Huelva 511 5.8 81 5.68 430 5.83
Almeria 600 6.8 124 8.70 476 6.45
Cordoba 608 6.9 109 7.65 499 6.77
Granada 871 9.9 158 11.09 713 9.67
Cadiz 1541 17.5 254 17.82 1287 17.45
Seville 1713 19.5 215 15.09 1498 20.31
Malaga 2511 28.5 403 28.28 2108 28.58
Qualitative variables
IVDU: Intravenous drug usersPage 4 of 9
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being diagnosed during the HAART era and older age at
the time of diagnosis.
Model for the Men
In the bivariate analysis, male intravenous drug users had
lower levels of health, i.e. they had higher YLLs, YLDs and
DALYs due to HIV/AIDS (YLL = 31.19, YLD = 4.01 and
DALY = 35.19) than those who did not use intravenous
drugs (YLL = 23.78, YLD = 3.52 and DALY = 27.30) (Table
5).
In terms of levels of health and the place of residence at
the time of diagnosis, living in Huelva (p = 0.039) and
Cadiz (p = 0.003) was found to be linked to higher YLLs
and higher DALYs (p = 0.039), living in Almeria (p =
0.030) and Malaga (p = 0.010) was to be linked to higher
YLDs, and living in Huelva (p = 0.039) and Cadiz (p =
0.001) was found to be linked to higher DALYs. In addi-
tion, a link was found between living in Granada at the
time of diagnosis and lower DALYs (p = 0.001).
Older age at the time of diagnosis was found to be linked
to lower Years of Life Lost due to the illness (Coefficient =
-20.437), lower Years of Life with Disability (Coefficient =
-20.17) and lower Disability-Adjusted Life Years (Coeffi-
cient = -16.411).
In the multivariate analysis with linear regression a model
was found which explained 64.4% (Coefficient of deter-
mination = 0.644) of the level of health (DALY). A higher
level of health (lower DALY) was found to be linked to
intravenous drug use, the province of residence, being
Table 2: Descriptive Analysis of the Population Studied. 
Total Women Men
Variable Mean (Stand. Dev.) Range Mean (Stand. Dev.) Range Mean (Stand. Dev.) Range
Age at diagnosis N = 8800 33.7 (9.31) 0.0–87 31.3 (10.5) 0.0–77.0 34.1 (9.0) 0.0–87.0
Survival in months N = 8800 49.6 (50.6) 0.1–236.4 54.7 (51.8) 0.1–234.4 48.7 (50.4) 0.0–236.4
Age At Time of Death. N = 5389 38.2 (9.5) 0.2–87.6 36.3 (10.5) 0.2–77.9 38.6 (9.3) 0.3–87.7
Years of Life Lost. N = 8796 29.06 (24.36) 0.0–82.50 26.82 (27.09) 0–82.5 29.49 (23.77) 0–80
Years of Life with Disability. N = 
8800
3.95 (4.06) 0.0–19.18 4.33 (4.16) 0.01–19.01 3.88 (4.04) 0.00–19.18
DALY. N = 8796 33.01 (21.98) 0.08–85.96 31.15 (24.78) 0.08–85.96 33.37 (21.38) 0.08–83.11
Quantitative variables
DALY: Disability-adjusted life years
Table 3: Bivariate Analysis for Women. 
VARIABLE YLL YLD DALY
Mean (Stand. Dev.) p-value Mean (Stand. Dev.) p-value Mean (Stand. Dev.) p-value
IVDU
No 23.44 (27.34) < 0.001 3.99 (3.88) 0.009 27.43 (25.39) < 0.001
Yes 29.46 (26.64) 4.58 (4.33) 34.03 (23.97)
Province of residence at diagnosis
Jaen 22.44 (26.25) 0.126 4.78 (4.44) 0.347 27.22 (23.61) 0.027
Huelva 30.22 (27.35) 0.252 4.51 (4.39) 0.704 34.73 (24.88) 0.186
Almeria 26.97 (27.09) 0.948 4.44 (3.63) 0.723 31.42 (24.92) 0.902
Cordoba 32.06 (26.84) 0.036 3.97 (4.60) 0.393 36.02 (23.96) 0.039
Granada 18.58 (25.27) < 0.001 5.06 (4.10) 0.020 23.63 (23.43) < 0.001
Cadiz 29.48 (27.02) 0.084 4.10 (4.24) 0.331 33.58 (24.63) 0.084
Seville 25.14 (27.67) 0.333 4.75 (4.14) 0.111 29.89 (25.24) 0.424
Malaga 28.00 (27.04) 0.300 3.91 (4.02) 0.014 31.91 (24.94) 0.469
Diagnosis Period
Up to and including 1996 35.89 (26.40) 4.92 (4.89) 40.81 (22.47)
1997 and 1998 16.57 (24.35) < 0.001 5.47 (2.77) 0.127 22.04 (21.97) < 0.001
1999 onwards 12.77 (21.48) < 0.001 2.53 (1.90) < 0.001 15.31 (20.54) < 0.001
Qualitative Variables
IVDU: Intravenous drug users
YLL: Life lost due to premature mortality
YLD: Years lost due to disability
DALY: Disability-adjusted life yearsPage 5 of 9
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of diagnosis (Table 6).
Discussion
The most innovative part of this study is the use of DALYs
to measure the level of health of patients in the sample
group. DALYs are a more holistic measurement than mor-
tality or survival rates to study the impact or "burden of
disease" associated with HIV/AIDS, because, as we know,
quality of life decreases as the disease progresses as a result
of its symptoms [13].
This study also contributes to knowledge of this area by
tackling the models separately for each sex, as there is
some debate surrounding the possible differences in fac-
tors which explain health scores between men and
women with HIV/AIDS. Based on biological factors, the
first studies carried out regarding the differences in HIV
prognosis between men and women found that the dis-
Table 4: Multivariate Analysis for Women. 
VARIABLE Constant Standard error p-value
Constant 44.775 2.609 < 0.001
IVDU
No
Yes 2.692 1.181 0.023
Province of residence at diagnosis
Granada
Almeria 2.512 2.616 0.337
Cadiz 4.829 2.213 0.029
Cordoba 5.681 2.725 0.037
Huelva 4.209 2.976 0.158
Jaen 0.429 2.972 0.885
Malaga 3.801 2.044 0.063
Seville 0.784 2.286 0.732
Period of diagnosis
Up to and including 1996
1997 and 1998 -17.458 1.745 < 0.001
1999 onwards -22.834 1.396 < 0.001
Age at diagnosis -0.298 .056 < 0.001
Coefficient of determination = 24.5%
IVDU: Intravenous drug users
Dependent variable: DALY
Table 5: Bivariate Analysis for Men. 
VARIABLE YLL YLD DALY
Mean (Stand. Dev.) p-value Mean (Stand. Dev.) p-value Mean (Stand. Dev.) p-value
IVDU
No 23.78 (22.49) < 0.001 3.52 (3.90) < 0.001 27.30 (20.43) < 0.001
Yes 31.19 (23.86) 4.01 (4.06) 35.19 (21.31)
Province of residence at diagnosis
Jaen 27.59 (25.05) 0.137 3.86 (3.90) 0.928 31.45 (22.65) 0.097
Huelva 31.78 (23.31) 0.039 3.66 (3.99) 0.241 35.44 (20.91) 0.039
Almeria 31.16 (23.50) 0.109 3.51 (3.82) 0.030 34.68 (21.32) 0.168
Cordoba 30.80 (23.97) 0.207 3.81 (4.61) 0.723 34.62 (21.08) 0.173
Granada 26.85 (24.17) 0.002 3.88 (3.95) 0.097 30.73 (22.07) 0.001
Cadiz 31.28 (23.29) 0.003 3.85 (3.96) 0.769 35.13 (20.86) 0.001
Seville 25.14 (27.67) 0.333 4.75 (4.14) 0.111 29.89 (25.24) 0.424
Malaga 30.24 (23.36) 0.182 3.69 (3.97) 0.010 33.93 (21.08) 0.150
Diagnosis Period
Up to and including 1996 36.28 (21.97) 4.22 (4.61) 40.50 (18.33)
1997 and 1998 20.81 (22.91) < 0.001 4.67 (3.03) 0.134 25.48 (20.36) < 0.001
1999 onwards 15.18 (21.06) < 0.001 2.42 (1.91) < 0.001 17.60 (20.03) < 0.001
Qualitative VariablesPage 6 of 9
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female patients died after a longer period. However, later
studies have come to different conclusions, attributing the
differences in prognosis to other factors [17]. In this study,
we have found that the factors related to levels of health
were the same for both sexes, although the relative risks
were different.
The prevalence of AIDS in Andalusia is lower than the
Spanish average, with 1.23 cases per 1000 inhabitants
[18], and it is the Spanish Autonomous Community with
the lowest percentage of female patients with HIV/AIDS.
This study found that the use of intravenous drugs was
related to lower levels of health. Intravenous drug use is
the most common means of transmission of HIV/AIDS in
Spain [3]. This link varies according to different factors, as
stated in the literature. Some studies have found differ-
ences between intravenous drug use and other routes of
infection in the mortality and survival rates in different
periods, both in Spain and in other European countries
[4,5,8]. However, some other studies do not reflect the
same results [19].
As HIV positive intravenous drug users lack information
and are excluded and discriminated against [1], some-
times rates of adherence to antiretroviral treatment are
"unacceptably low" amongst drug users. In addition, as
intravenous drug users have a particular sociocultural
environment and have to deal with drug addiction as well
as their HIV infection, it is difficult to monitor these
patients and for them to adhere correctly to their treat-
ment programmes, and this compromises the effective-
ness of treatment and results in resistance to it [20], thus
affecting quality of life and levels of health.
A link was found between diagnosis after the introduction
of HAART (1997 and 1998, 1999 onwards) and a higher
level of health amongst patients with HIV/AIDS. This
reflects the effectiveness of the treatment. Most studies
have shown that HAART is more effective than the tech-
nologies used before its introduction [21-24].
The differences in levels of health according to the prov-
ince of residence at the time of diagnosis may be a result
of different clinical practices in the different healthcare
centres. It is also possible that different cultural factors
influence patients' access to healthcare services. Other
studies must be carried out in order to evaluate these dif-
ferences.
An older age at time of diagnosis linked to lower DALY, it
could be related to shorter life expectancy. This result
could be used as an argument in the debate about whether
it is appropriate to assign age-related weightings in the cal-
culation of DALYs. However, some researchers believe
that if age is taken into account, other factors such as
social roles (occupation or productivity), or income,
would also have to be considered [25]. The main problem
is whether a DALY (or a QALY) has the same value for all
patients. This equality debate centres around a utilitarian
philosophy and is, of course, a matter of personal opin-
ion. However, any other alternative would make it neces-
sary to specify which criteria mean that a DALY for a child
Table 6: Multivariate Analysis for Men. 
VARIABLE Constant Standard error p-value
Constant 52.005 1.331 < 0.001
IVDU
No 1
Yes 2.857 0.545 < 0.001
Province of residence at diagnosis
Granada 1
Almeria 1.886 1.100 0.086
Cadiz 0.585 0.873 0.503
Cordoba 0.045 1.088 0.967
Huelva 2.228 1.132 0.049
Jaen -1.332 1.204 0.268
Malaga 0.460 0.810 0.570
Seville -2.221 0.848 0.009
Period of diagnosis
Up to and including 1996 1
1997 and 1998 -13.530 0.651 < 0.001
1999 onwards -19.954 0.556 < 0.001
Age at diagnosis -0.427 0.027 < 0.001
Coefficient of determination = 64.4%
IVDU: Intravenous drug users
Dependent variable: DALYPage 7 of 9
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another person.
The factors linked to the level of health were the same for
both sexes. However, the coefficient of determination was
different, and was higher amongst the men in the sample
group than amongst the women. This suggests that there
are other variables at play which are not specified in the
model (not available in the database), and which lead to
differences and asymmetry between the two groups. The
data merely allow us to make speculative suggestions
about what these other variables may be, and they could
include access to the healthcare system, social support and
even therapeutic bias.
One limiting factor of this study is the fact that it did not
include clinical factors, such as CD4 levels, the viral load
or severity of the illness, number of years as an HIV carrier,
adherence to treatment or coinfection, and as such the
mortality rate was not adjusted to take these parameters
into account. We would recommend that these data are
included in future research so that the results of this study
can be confirmed.
Advances in HIV/AIDS treatment have led to greater sur-
vival rates and limited quality of life amongst patients,
with a considerable burden of disease. Healthcare services
must meet the challenge of offering the care required for
HIV/AIDS patients, providing them with the treatment
available and facilitating access to the whole population.
In this way, factors which are extrinsic to the patient's clin-
ical situation, such as the province of residence at the time
of diagnosis or intravenous drug use, will cease to be
related to the burden of disease. However, other socio-
economic attributes could have played important role
independent of treatment and care, more so when inject-
ing drug users constituted the bulk of the study popula-
tions. Improvement of HIV care would certainly improve
DALY but not completely because HIV is not simply a
medical disease.
Conclusion
A higher level of health (lower DALY) amongst both men
and women was found to be linked to intravenous drug
use, the province of residence, being diagnosed during the
HAART era and older age at the time of diagnosis.
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